Cellestis' tuberculosis diagnostic:
This article was originally published in Clinica
Executive Summary
Melbourne, Australia-based Cellestis has received regulatory approval in South Korea for its tuberculosis (TB) diagnostic, QuantiFERON-TB Gold In-Tube. The test is based on the measurement of IFN-gamma secreted from stimulated T cell lymphocytes previously exposed to Mycobacterium tuberculosis infection. The assay involves an overnight culture of whole blood with tuberculin and control antigens, followed by detection of IFN-gamma in a rapid, single-step, sandwich ELISA. The prevalence of TB in Korea has been reported as 135 per 100,000 people, and BCG vaccination is mandatory. Cellestis will market the test in the Korea via its distributor, Woongbee MeDiTech.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.